Gene-Editing shot aims to fix rare lung and liver disease
Disease control
Recruiting now
This early-stage trial tests a new gene-editing medicine called TSRA-196 in 72 adults with a severe form of alpha-1 antitrypsin deficiency (the PiZZ genotype) who have lung or liver problems. The treatment is given by IV infusion and aims to raise levels of a protective protein. …
Phase: PHASE1, PHASE2 • Sponsor: Tessera Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC